Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs  by Yarbrough, William M. et al.
Matrix metalloproteinase inhibition modifies left ventricular
remodeling after myocardial infarction in pigs
William M. Yarbrough, MD
Rupak Mukherjee, PhD
Theresa A. Brinsa, BS
Kathryn B. Dowdy, BS
Amelia A. Scott, BS
G. Patricia Escobar, DVM
Cassandra Joffs, MD
David G. Lucas, MD
Fred A. Crawford, Jr, MD
Francis G. Spinale, MD, PhD
Background: Global and regional shape changes that occur within the left
ventricular wall after myocardial infarction have been termed infarct
expansion. A potential mechanism for this postinfarction remodeling is
activation of the matrix metalloproteinases. Accordingly, the present
study examined the effects of matrix metalloproteinase inhibition on left
ventricular global geometry after myocardial infarction in pigs.
Methods: Myocardial infarction was created in pigs by means of occlu-
sion of the first and second obtuse marginal branches of the circumflex
coronary artery, resulting in a uniform left ventricular free wall infarct
size of 21%  2%. At 5 days after infarction, the pigs were randomized
to undergo broad-spectrum matrix metalloproteinase inhibition (n  9;
PD166793, 20 mg  kg1  d1 by mouth) or myocardial infarction alone
(n  8). Ten pigs served as noninfarction control animals. Left ventricular end-
diastolic area, determined by means of echocardiography, was measured 8 weeks
after infarction.
Results: Left ventricular end-diastolic area increased in both the myocardial infarc-
tion plus broad-spectrum matrix metalloproteinase inhibition and myocardial in-
farction only groups compared to reference control animals (3.7 0.2 cm2), but was
reduced with broad-spectrum matrix metalloproteinase inhibition compared to myo-
cardial infarction alone (4.5  0.2 vs 4.9  0.2 cm2, respectively; P  .05).
Regional radial stress within the infarct region increased in both infarction groups
when compared to values obtained from reference control animals (599  152
g/cm2), but was attenuated in the myocardial infarction plus broad-spectrum matrix
metalloproteinase inhibition group compared to the myocardial infarction alone
group (663  108 vs 1242  251 g/cm2, respectively; P  .05). Similarly, regional
myocardial stiffness increased in both the myocardial infarction plus broad-spec-
trum matrix metalloproteinase inhibition and the myocardial infarction only groups
compared with that observed in reference control animals (14 1 rkm, P .05) but
was lower with broad-spectrum matrix metalloproteinase inhibition than with myo-
cardial infarction alone (42  6 vs 68  10 rkm, respectively; P  .05).
Conclusions: Matrix metalloproteinase inhibition reduced postinfarction left ven-
tricular dilation, reduced regional myocardial wall stress, and modified myocardial
material properties. These unique findings suggest that increased myocardial matrix
metalloproteinase activation after infarction contributes directly to the left ventric-
ular remodeling process.
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Left ventricular (LV) regional myocardialdysfunction and remodeling, which occursimmediately after myocardial infarction(MI), can persist long after the acute in-sult.1,2 In the post-MI period significant cel-lular and extracellular remodeling may oc-
cur within both the MI and nonischemic remote myocardial
regions.3 The summation of these cellular and extracellular
events during the post-MI period results in changes in LV
geometry, which has been termed infarct expansion.4 It has
been postulated that the degree of LV remodeling and
subsequent infarct expansion is related to clinical outcome
after MI.1
An endogenous family of enzymes that have been iden-
tified to be responsible for tissue remodeling in a number of
disease states is the matrix metalloproteinases (MMPs).5-9
Increased MMP expression and activity have been reported
to occur in patients with end-stage heart failure,5 as well as
in several animal models of developing LV dysfunction.6-9
Although these past studies suggest that increased MMP
activity contributes to the myocardial remodeling process,
the mechanistic link between MMP activation and post-MI
infarct expansion has not been directly examined. Accord-
ingly, the present study tested the central hypothesis that
increased myocardial MMP activation occurs in the post-MI
period and thereby is a contributory mechanism for infarct
expansion. Past studies have demonstrated that administra-
tion of broad-spectrum MMP inhibitors can influence the
myocardial remodeling process.7-9 For example, MMP in-
hibition has been demonstrated to attenuate the degree of
LV dilation caused by several pathologic stimuli.7,8 How-
ever, the effects of MMP inhibition on infarct expansion and
regional myocardial function in the post-MI setting remain
unknown. Accordingly, the overall goal of this study was to
employ MMP inhibition in the post-MI period in a porcine
model to directly measure the effects of MMP inhibition on
the temporal progression of changes in global and regional
LV geometry.
Methods
Yorkshire pigs (23-25 kg, n  17, Hambone Farms, Orangeburg,
SC) were instrumented to measure the effects of MMP inhibition
on global LV geometry after MI. Ten weight-matched noninstru-
mented pigs were used as reference, non-MI control animals.
Broad-spectrum MMP inhibition was instituted during the post-MI
period, and changes in global LV geometry were examined at 8
weeks. All animals were treated and cared for in accordance with
the National Institutes of Health “Guide for the Care and Use of
Laboratory Animals” (National Research Council, Washington,
DC, 1996).
MI Induction
Before instrumentation and MI induction, transthoracic 2-dimen-
sional and M-mode echocardiographic studies (2.25-MHz trans-
ducer, ATL) were performed, as previously described.7 Following
baseline echocardiographic measurements, the animals were ad-
ministered bretylium tosylate (INN: bretylium tosilate; 250 mg;
American Regent Laboratories), were anesthetized with isoflurane
(2.5%, 2 L) and nitrous oxide (1.5 L/min), and were prepared in a
sterile manner, as described previously.7 The pericardium was
opened through a left thoracotomy, and the first 2 obtuse marginal
branches of the circumflex coronary artery were identified and
ligated. A continuous lidocaine HCl infusion (60 mg  kg1  h1,
Baxter Healthcare Corp) was used to suppress dysrhythmia. The
pericardium was left open, and the wound was closed in layers.
After recovery from instrumentation and MI creation, pigs were
randomized to receive either placebo (n  8) or broad-spectrum
MMP inhibition (n  9, PD166793, or (S)-2-(4-bromobiphenyl-
4-sulfonylamino)-3-methyl-butyric acid, 20 mg  kg1  d1 by
mouth), which was initiated 5 days after MI induction. Custom
timing devices were used to consistently deliver oral meatballs to
the pigs. Pigs randomized to MMP inhibition received meatballs
containing PD166793. On the basis of ex vivo MMP assays, this
dosing regimen for PD166793 has been previously demonstrated
to achieve plasma levels (8-10 mol/L) sufficient to provide
pharmacologic inhibition for the MMP-1, MMP-2, MMP-3,
MMP-7, and MMP-9 species.7 Importantly, plasma levels of
PD166793 achieved by this regimen did not exhibit inhibitory
activity against other proteolytic systems that could potentially
contribute to LV remodeling. These alternate proteolytic systems
include angiotensin-converting enzyme, endothelin-converting en-
zyme, neutral endopeptidase, and tumor necrosis factor -convert-
ing enzyme.7
Regional Stress and Stiffness After MI
Echocardiographic measurements were repeated 8 weeks after MI.
LV short-axis images gated to end-diastole were digitized and used
to compute end-diastolic cross-sectional area and regional radial
stress within the septal and posterolateral LV walls (Figure 1). In
brief, epicardial and endocardial borders were determined by
means of electronic planimetry, and centers of mass were com-
puted. A diameter of the epicardial border was constructed such
that the line included the center of mass and was perpendicular to
a second line connecting the papillary muscles. Posterolateral and
septal radii were measured as the distance of their respective
endocardial borders from the center of mass.
After establishment of a surgical plane of anesthesia, a 7F
introducer was placed into the right carotid artery to monitor aortic
pressures (Statham P23ID, Gould). A median sternotomy was
performed, and a vessel loop was placed around the inferior vena
cava to perform transient caval occlusion. A precalibrated mi-
crotipped transducer (7.5F, Millar Instruments Inc) was sutured
into the LV apex. Two pairs of piezoelectric crystals (2 mm,
Sonometrics) were positioned within the midmyocardium to mea-
sure segmental wall motion. The first crystal pair was placed
between the first and second diagonal branches of the left anterior
descending artery. The second crystal pair was placed within the
MI region between the first and second obtuse marginal branches.
Pressure waveforms and crystal signals were digitized for subse-
quent analysis at a sampling frequency of 100 Hz (Pentium pro-
cessor).
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Figure 1. Top, Regional stress in the posterolateral and septal walls, as determined on the basis of echocardio-
grams recorded at end-diastole. A representative image obtained 8 weeks after MI and an image schematic are
shown (top, left, and right, respectively). Filled circle, Center of mass; Rm, posterolateral radius; Rs, septal radius;
hm, posterolateral wall thickness; hs, septal wall thickness. Middle, LV end-diastolic cross-sectional area
increased from baseline in both MI groups at 8 weeks after MI but to a lesser degree with MMP inhibition. Bottom,
Regional radial stress in the septal wall increased from control values in the MI only group. In the posterolateral
wall regional radial stress increased from control values in the MI only group but was normalized in the MIMMPi
group. *P < .05 versus reference control values; P < .05 versus MI only values.
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All measurements were performed after a 60-minute equilibra-
tion period. Peak LV pressure and dimensions determined from
echocardiographic images were used to compute regional radial
stress from established formulas.10,11 The regional myocardial
stiffness constant (rKm) was computed by using the logarithmic
transformation of the exponential end-diastolic stress-strain rela-
tionship as follows:
  A e(rKm )  B,
where  is regional end-diastolic wall stress, A and B are
constants, and  is the regional strain.12
At the conclusion of the study, the left ventricle was harvested
and placed in iced Krebs solution. The MI border region was
defined as a 0.5-cm rim of tissue surrounding the MI. The LV free
wall was dissected into the MI region, the border region, and the
remote region. Relative MI size was determined by using gravi-
metric methods. Full-thickness 0.5-cm sections from each region
were immersed in fresh fixative. Slices 4 m in thickness were cut
from the specimens and mounted on glass slides. The slices were
rehydrated and stained by using picrosirius histochemical tech-
niques, as previously described.13 The sections were digitized at a
magnification of 400 and analyzed with an image-analysis sys-
tem (Sigma Scan/Image, Jandel). The percentage area of extracel-
lular staining was computed from 15 random fields within the
midmyocardium to exclude large epicardial arteries and veins and
any cutting or compression artifact.
Data Analysis
All measurements were performed in a blinded fashion with re-
spect to treatment. Changes in global LV dimensions were com-
pared between the MI groups by using 2-way analysis of variance
(ANOVA). For the terminal studies, hemodynamic measurements
and changes in LV regional function were compared between the
reference control, MI only, and MIMMP inhibitor (MMPi)
groups by means of ANOVA. Similarly, myocardial collagen
content was compared between the same groups by using a 2-way
ANOVA. Specific pairwise comparisons were performed with a
Bonferroni adjusted t test. Statistical analysis was performed by
using statistical software programs (BMDP Statistical Software
Inc, University of California Press), with results presented as the
mean  SEM.
Results
All pigs enrolled in the present study completed the proto-
col. Occlusion of the first 2 obtuse marginal branches of the
circumflex coronary artery resulted in a uniform LV free
wall MI size of 21%  2%, and there was no difference
between the 2 groups. At 8 weeks after MI, mean arterial
pressures, LV peak pressures, and LV end-diastolic pres-
sures for both MI groups were not different from reference
control values, demonstrating that MI induction did not
cause hemodynamic compromise (Table 1).
LV end-diastolic cross-sectional area at 8 weeks after MI
was higher in both MI groups compared with reference
control or baseline values. However, at 8 weeks after MI,
the LV end-diastolic cross-sectional area was lower in the
MIMMPi group compared to the MI only group (Figure
1). Radial wall stress was increased in the MI and septal
regions in the MI only group (Figure 1) compared with
reference control values. In the MI region radial stress was
lower in the MIMMPi group compared with that in the MI
only group. In the remote region myocardial stiffness values
were higher than reference control values in both MI groups
(MI only, 22.9  4.3 rkm; MIMMPi, 25.4  3.6 rkm;
P .05 vs control group, 13.5 1.9 rkm). In the MI region
myocardial stiffness was lower in the MIMMPi group
compared with that in the MI only group (MI only, 67.5 
9.5 rkm; MIMMPi, 41.9  5.9 rkm; P  .05) but re-
mained higher than in the control group (13.8  1.4 rkm,
P  .05) in both MI groups.
Fibrillar collagen percentage areas (Figure 2) measured
in myocardial samples from the remote, border, and MI
regions were higher than reference control values in both
MI groups (MI only group: remote, 7.3%  0.5%; border,
9.9%  0.8%; MI region, 21.1%  1.4%; MIMMPi
group: remote, 8.8%  0.6%; border, 8.5%  0.6%; MI
region, 22.6%  2.0%; all values  .05 versus control
values of 5.6%  0.3%). Collagen content within the MI
region was increased compared with that in the remote and
border regions (Figure 2). There were no region-specific
differences in collagen content between the 2 MI groups.
Discussion
It is estimated that over one million patients within the
United States incur LV injury as a result of MI annually.14
Although new pharmacologic and interventional therapies
have improved the outcome of an acute MI, the long-term
sequelae remain a significant clinical problem. Specifically,
LV remodeling after MI can result in LV dilation and has
been termed infarct expansion.4 The MMPs are a family of
zinc-dependent enzymes that may influence tissue remod-
eling processes. MMPs are increased in a number of patho-
logic conditions.3,5 Several past studies using rodent models
have suggested a potential association between increased
MMP activity and post-MI LV remodeling.6,9,15 The present
study examined the cause-and-effect relationship between
MMP activation and post-MI infarct expansion by using a
porcine model that exhibits a coronary artery anatomy sim-
ilar to that of human subjects.16 The unique findings of this
study were 2-fold. First, concomitant MMP inhibition dur-
ing the post-MI period attenuated global LV dilation. Sec-
ond, MMP inhibition reduced regional radial wall stress and
influenced myocardial material properties of the MI region.
Thus the present study clearly demonstrated that MMP
activation contributes to post-MI LV remodeling and rep-
resents a novel therapeutic target.
MMPs and Post-MI Remodeling
A number of MMP species have been identified as present
within the myocardium.17 Past clinical and experimental
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Figure 2. For legend see opposite page.
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studies have demonstrated that LV remodeling in various
cardiovascular disease states is accompanied by induction
of MMP species.5-8 Pharmacologic MMP inhibition has
been demonstrated to reduce LV remodeling in certain
animal systems.6-9 Rodent models of MI have provided
evidence that increased MMP activation contributes to
post-MI LV remodeling.6,9,15 For example, Ducharme and
colleagues15 demonstrated that the degree of post-MI LV
dilation was reduced in a genetically modified mouse model
in which MMP-9 expression was abolished. Rohde and
coworkers9 demonstrated that broad-spectrum MMP inhibi-
tion for a period of 4 days resulted in an attenuation of
post-MI LV dilation.9 However, several questions remain
unanswered from these rodent studies. First, in the study
performed by Rohde et al, MMP inhibition was instituted
for a short period of time after MI. Whether, and to what
degree, longer durations of MMP inhibition would influence
myocardial remodeling remains unknown. Second, the port-
folio of MMPs expressed by rodents differs from that ex-
pressed in the human myocardium.8 Third, changes in LV
regional geometry and material properties after MI are
unable to be assessed in rodent models. The results of the
present study demonstrated that chronic MMP inhibition for
2 months attenuated LV dilation after MI.
Although the causes for myocardial structural changes
after MI are likely multifactorial, the present study demon-
strated that increased myocardial MMP activity is likely an
important determinant of post-MI remodeling. However, it
must be recognized that other systemic factors can influence
the course of post-MI LV remodeling. Specifically, MI
induction has been reported to increase the myocardial
expression of bioactive peptides. For example, increased
activation of the renin-angiotensin-aldosterone and sympa-
thetic adrenergic systems have been reported to occur after
MI.17 Interruption of these neurohormonal systems has been
demonstrated to confer beneficial effects with respect to
post-MI LV remodeling.18,19 Past clinical studies have dem-
onstrated that angiotensin-converting enzyme inhibition in
the post-MI period improved survival and reduced post-MI
LV dilation.18 The present study did not directly assess the
activational state of these neurohormonal pathways during
the post-MI period. However, the size and location of the
MI were chosen to prevent acute changes in ejection per-
formance and thereby to avoid confounding alterations in
systemic hemodynamics and neurohormonal systems. Al-
though infarcts of similar sizes within clinical settings have
been shown to be associated with post-MI LV dilation,2
future studies examining the effects of MMP inhibition on
LV remodeling in the post-MI period superimposed on
reduced ejection performance are warranted. Nevertheless,
TABLE 1. Hemodynamics after chronic MI: Effects of MMP inhibition
Control MI MI  MMPi
Global function
Heart rate (beats/min) 97 7 108 9 93 7
Cardiac output (L/min) 3.26 0.18 3.95 0.48 3.54 0.35
Mean aortic pressure (mm Hg) 105 4 114 5 106 5
Mean pulmonary artery pressure (mm Hg) 18 1 17 1 18 2
LV pressures and function
Peak systolic pressure (mm Hg) 129 3 138 5 134 4
End-diastolic pressure (mm Hg) 10 1 10 1 11 1
Stroke volume (mL) 35.1 3.2 37.1 3.4 38.6 2.6
Fractional shortening (%) 43.1 1.8 34.2 2.9* 33.8 1.8*
Peak  dP/dt (mm Hg/s) 2249 186 2261 288 2057 103
Sample size (n) 10 8 9
Values are presented as mean  SEM. MI, eight weeks after MI by occlusion of the first 2 obtuse marginals (OM1, OM2) of the circumflex artery; MMPi,
concomitant MMP inhibition with PD166793 (20 mg  kg1  d1 by mouth).
*P  .05 versus control.
Figure 2. Top, Representative picrosirius-stained sections viewed by using polarization microscopy. A well-
developed collagen weave was observed in control sections and was increased in the remote and border regions
after MI. A thickened collagen weave, consistent with a well-formed scar, was observed in the MI region. (Original
magnification 400.) Bottom, Quantitative histomorphometry of LV sections at 8 weeks after MI. Fibrillar collagen
content was increased from reference control values in all regions after MI. Collagen content within the MI region
was increased compared with that in the remote and border regions. Relative collagen content was unchanged
from MI only values with MMP inhibition. *P < .05 versus reference control values; ‡P < .05 versus remote and
border values.
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the results of the present study coupled with results of past
reports suggest that a downstream molecular trigger for
infarct expansion and post-MI LV remodeling is MMP
activation.
MMPs and Regional Structure and Function
An important manifestation of LV remodeling is changes in
LV wall stress patterns and material properties.7,8 Specifi-
cally, the reduction in LV free wall thickness, which occurs
rapidly after the onset of MI,1,2,4,10 can cause increased
circumferential and radial wall stress in the MI region. In
the present study LV remodeling after MI was accompanied
by increased radial stress within the MI region, which was
attenuated by MMP inhibition. Thus although remaining
speculative, a secondary effect of MMP inhibition after MI
might have been the reduction of stress-induced MMP ac-
tivation. Material properties of the myocardium are deter-
mined by various factors, including the content, composi-
tion, and structure of the extracellular matrix.20,21 In the
present study fibrillar collagen content was increased in
both the remote and MI regions after MI, which was asso-
ciated with increased regional myocardial stiffness. Colla-
gen accumulation within the remote region might not have
been a replacement fibrosis but might have instead reflected
increased interstitial collagen deposition caused by the hy-
pertrophic response of the remote viable myocardium.22 The
relative fibrillar collagen content within the MI region did
not appear to be quantitatively altered by MMP inhibition.
A recent investigation that examined chronic MMP inhibi-
tion in a rabbit model of MI similarly reported no difference
in regional collagen content, irrespective of MMP inhibi-
tion.23 Moreover, a past study has demonstrated that MMP
inhibition can influence myocardial collagen structure.7 The
present study demonstrated that MMP inhibition instituted 5
days after MI did not influence the initial myocardial re-
sponse to injury and resultant collagen deposition. The
relative collagen content and regional stiffness in the remote
region was increased after MI and was unaffected by MMP
inhibition. However, MMP inhibition reduced myocardial
stiffness properties in the MI region. The apparent regional
disparity between the effects of MMP inhibition on collagen
deposition and myocardial stiffness properties are likely
caused by the distinctly different patterns of collagen accu-
mulation between the remote and MI regions. These results
suggest that MMP inhibition after MI prevents degradation
of nascent myocardial matrix without stimulation of colla-
gen biosynthesis. Past in vitro studies suggest that changes
in collagen alignment might alter material properties.24
Thus although remaining speculative, MMP inhibition
might have altered the geometric orientation of collagen
within the myocardium after MI, accounting for the differ-
ence observed in regional myocardial stiffness.
Summary and Future Directions
The balance between MMP activity and collagen deposition
within the MI region after an acute MI might determine the
initial wound-healing response and long-term sequelae of
post-MI LV remodeling. In transgenic mouse models inter-
ference of early MMP activation was associated with ad-
verse LV remodeling and abnormal post-MI wound-healing
response.15 Accordingly, the present study deployed MMP
inhibition 5 days after MI to avoid the confounding influ-
ences surrounding the acute phase of an MI, as well as the
potential deleterious effects of early modulation of MMP
activity. By using this strategy, the present study demon-
strated that MMP inhibition attenuated LV remodeling for
up to 2 months after MI. Because the current treatment
paradigms for an acute MI result in an intrahospital duration
of 5 days or less,25 then the results of the present study have
clinical implications in that this represents a practical tem-
poral initiation of a treatment regimen that translated to a
beneficial effect on the post-MI LV remodeling process. In
the present study broad-spectrum MMP inhibition was used.
Past clinical studies have demonstrated that certain MMP
species are upregulated with end-stage heart failure and LV
remodeling.5 Therefore future studies that identify specific
MMP species upregulated after MI and that tailor species-
specific MMP inhibition would be appropriate. Neverthe-
less, the unique results of the present study demonstrated
that post-MI MMP inhibition in a large-animal model at-
tenuated the degree of global LV dilation.
We thank Dr Mary K. King, Mr Jeffrey A. Sample, and Mrs
Jennifer W. Hendrick for assisting with this project. We also thank
Dr J. Thomas Peterson for the gift of the MMP inhibitor.
References
1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial
infarction. Experimental observations and clinical implications. Cir-
culation. 1990;81:1161-72.
2. Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger
JA. Relation of initial infarct size to extent of left ventricular remod-
eling in the year after acute myocardial infarction. J Am Coll Cardiol.
1995;25:567-73.
3. Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by
fibrous tissue after infarction in rats. J Lab Clin Med. 2000;135:316-
23.
4. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial
infarction: pathophysiology and therapy. Circulation.
2000;101:2981-8.
5. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T,
et al. A matrix metalloproteinase induction/activation system exists in
the human left ventricular myocardium and is upregulated in heart
failure. Circulation. 2000;102:1944-9.
6. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metal-
loproteinase and tissue inhibitor expression during heart failure pro-
gression in the infarcted rat. Cardiovasc Res. 2000;46:307-15.
7. Spinale FG, Krombach RS, Coker ML, Mukherjee R, Thomas CV,
Houck WV, et al. Matrix metalloproteinase inhibition during the
development of congestive heart failure: effects on left ventricular
dimensions and function. Circ Res. 1999;85:364-76.
8. Peterson JT, Hallak H, Johnson L, Hua L, O’Brien PM, Sliskovic DR,
et al. Matrix metalloproteinase inhibition attenuates left ventricular
Surgery for Acquired Cardiovascular Disease Yarbrough et al
608 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
A
CD
remodeling and dysfunction in a rat model of progressive heart failure.
Circulation. 2001;103:2303-9.
9. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH,
Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates
early left ventricular enlargement after experimental myocardial in-
farction in mice. Circulation. 1999;99:3063-70.
10. Jugdutt BI, Michorowski BL. Role of infarct expansion in rupture of
the ventricular septum after acute myocardial infarction: a two-dimen-
sional echocardiographic study. Clin Cardiol. 1987;10:641-52.
11. Fujii AM, Gelpi RJ, Mirsky I, Vatner SF. Systolic and diastolic
function during atrial pacing in conscious dogs with left ventricular
hypertrophy. Circ Res. 1988;62:462-70.
12. Mirsky I, Pasipoularides A. Clinical assessment of diastolic function.
Prog Cardiovasc Dis. 1990;32:291-318.
13. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative
assessment of myocardial collagen with picosirius red staining and
circularly polarized light. Basic Res Cardiol. 1994;89:397-410.
14. Anonymous. Heart and stroke statistical update. Coronary heart dis-
ease (ICD/9 410-414). Dallas, Tex: American Heart Association;
2002.
15. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE,
et al. Targeted deletion of matrix metalloproteinase-9 attenuates left
ventricular enlargement and collagen accumulation after experimental
myocardial infarction. J Clin Invest. 2000;106:55-62.
16. Weaver ME, Pantely GA, Bristow JD, Ladley HD. A quantitative
study of the anatomy and distribution of coronary arteries in swine in
comparison with other animals and man. Cardiovasc Res. 1986;20:
907-17.
17. Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs. New
York: Oxford University Press; 2000. p. 223.
18. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohor-
monal activation following acute myocardial infarction. Am Heart J.
1993;126:1068-76.
19. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications
for ACE inhibitors in the early treatment of acute myocardial infarc-
tion: systematic overview of individual data from 100,000 patients in
randomized trials. Circulation. 1998;97:2202-12.
20. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res.
2000;46:250-6.
21. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI.
Collagen remodeling of the pressure-overloaded, hypertrophied non-
human primate myocardium. Circ Res. 1988;62:757-65.
22. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of
myocardial fibrosis. J Mol Cell Cardiol. 1989;21(suppl 5):121-31.
23. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-
Morrow L, et al. Selective matrix metalloproteinase inhibition reduces
left ventricular remodeling but does not inhibit angiogenesis after
myocardial infarction. Circulation. 2002;105:753-8.
24. Wu JZ, Herzog W. Elastic anisotropy of articular cartilage is associ-
ated with the microstructures of collagen fibers and chondrocytes.
J Biomech. 2002;35:931-42.
25. McGovern PG, Jacobs DR Jr, Shahar E, Arnett DK, Folsom AR,
Blackburn H, et al. Trends in acute coronary heart disease mortality,
morbidity, and medical care from 1985 to 1997. the Minnesota heart
survey. Circulation. 2001;104:19-24.
Discussion
Dr Ralph J. Damiano, Jr (St Louis, Mo). You did not measure
any specific protein levels in this study?
Dr Yarbrough. No.
Dr Damiano. Have you looked at the different MMPs? Also,
what evidence do you have that these inhibitors do not also inhibit
other proteinases, and have you looked at nonspecific proteinase
inhibitors and their effects on LV remodeling in your model?
Dr Yarbrough. Thank you. We constructed a pharmacologic
strategy in the following way. A pure MMP species was combined
with a fluorogenic substrate specific for that particular species, for
example, MMP-3. In combination, MMP-3 degrades the substrate
and releases measurable fluorogenic byproducts. Activity for
MMP-3 is thus determined by assessing the amount of fluorogenic
byproducts present in the system. The next step involves the
introduction of an MMP-3 inhibitor. The concentration of the
MMP inhibitor is increased until the activity of the MMP species
decreases by 50% and its inhibitory concentration of 50% is
determined.
The same technique can be used to verify that other metallo-
proteinases, such as angiotensin-converting enzyme (ACE), are not
affected. ACE can be included in the same system as MMP-3,
MMP-3’s substrate, and MMP-3’s inhibitor. If a substrate for ACE
is also included and ACE activity is unaffected by MMP inhibi-
tion, then it might be concluded that the MMP inhibitor is specific
for only its MMP species. By applying this strategy to various
MMP species and other enzymes, specificity of MMP inhibitors
can be determined.
There are over 20 MMP species. We have not performed this
strategy for each of the 20 species. However, we have examined
those MMPs known to be associated with MI and ventricular
remodeling, such as MMPs 2, 3, 8, 9, and 13. Therefore we do not
believe that our pharmacologic strategy with MMP inhibitors
hinders other serine proteinases or metalloproteinases, such as
ACE.
We did not examine specific MMP levels in our broad-spec-
trum MMP inhibition study. We are still in the process of analyz-
ing data from our selective MMP inhibitor study, and we do
anticipate assessing specific MMP levels in the near future, but I
do not have this data at this time.
As far as LV remodeling is concerned, some investigators have
suggested that broad-spectrum MMP inhibition administered after
MI might cause fibrosis. Intuitively, if MMPs degrade collagen
and inhibit MMPs, then you might presume that myocardial fibro-
sis occurs over a period of time. However, our data do not support
that presumption.
In our broad-spectrum study, once the hearts were explanted,
the MI region, the border region, and the remote regions were
sectioned. Collagen content was assessed in each of those regions
in pigs randomized to MMP inhibition and MI and those random-
ized to MI alone. In both MI groups (the MI only and the MI plus
MMP inhibitor group) collagen content in each region was greater
than that observed in control pigs. However, there was no difference
at all between the MI groups. Therefore collagen content was not
increased by MMP inhibition. That finding has also been supported by
another study recently published in Circulation, which used a
rabbit model of MI. These investigators found no difference in
collagen content. However, they only examined the MI sections.
Mr Magdi H. Yacoub (London, United Kingdom). These are
indeed very impressive results. My question to you is, have you
looked at remodeling at the cellular level, for example, the size of
the myocytes or gene expression, calcium-handling proteins, or the
-myosin heavy chain? That would be very interesting.
The second question is, have you looked at TIMPs?
Dr Yarbrough. Those are very good questions, but I do not
have an answer for them yet. If we were to look at myocytes, we
could perform cross-sectional area studies. We did not include this
technique with our broad-spectrum study. However, we would
expect to see myocyte hypertrophy. We do not want to eliminate,
whether using broad-spectrum or selective MMP inhibition, the
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ability of remaining remote viable myocytes to respond to the MI
and compensate. Therefore when we do perform those studies in
future investigations, we expect to see hypertrophy in remote
borders.
Mr Yacoub. What about gene expression?
Dr Yarbrough. We have not looked at that yet. That would be
something that we need to investigate, but we have not performed
any gene studies with the broad-spectrum study.
Dr Frank W. Sellke (Boston, Mass). You mentioned that ACE
inhibition might actually inhibit MMP activation. Is this the pre-
dominant reason why captopril and other ACE inhibitors might
have a beneficial effect on post-MI remodeling, and is there
information regarding the pattern of the effect of ACE inhibition
on MMP expression?
Dr Yarbrough. I hope I did not say that ACE inhibition
inhibited MMPs. What I was trying to get across was that both
pathways, the ACE or RAS pathway, and the MMP pathway can
result in LV remodeling after MI. These systems interact. MMP
inhibitors might actually tone down stimulation of the ACE or
RAS system, such that it does not continue to stimulate remodeling
after MI. A possible distinction between these systems regards
speed.
Head to head, in a study of congestive heart failure in paced
pigs, both ACE inhibition and broad-spectrum MMP inhibition
attenuated LV remodeling by approximately 30%. But we can
likely achieve that 30% attenuation much more quickly with the
broad-spectrum and selective MMP agents, at least in a post-MI
model, when compared with use of ACE inhibitors.
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